Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis by R. Gualtierotti et al.
PRACTICAL APPROACH/CME ARTICLE
Practical Management of Cardiovascular
Comorbidities in Rheumatoid Arthritis
Roberta Gualtierotti . Nicola Ughi . Giovanni Marfia .
Francesca Ingegnoli
Received: April 24, 2017
 The Author(s) 2017. This article is an open access publication
ABSTRACT
Cardiovascular (CV) comorbidities are a fre-
quent extra-articular manifestation of rheuma-
toid arthritis (RA). Cardiovascular disease (CVD)
with accelerated atherosclerosis is a major cause
of morbidity and mortality in patients with RA.
Subclinical CVD may be present since the early
phase of RA. Not only traditional but also
non-traditional CV risk factors are involved in
the pathogenesis of RA-related CVD. Due to the
lack of specifically designed randomized clinical
trials, it is still unclear which tools to use to
perform CV risk assessment, how to interpret
the results and which interventions are appro-
priate in RA patients both to prevent and to
manage CVD. Based on the available evidence,
we propose a practical approach.
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INTRODUCTION
Rheumatoid arthritis (RA) is a common chronic
inflammatory joint disease, which affects up to
1% of the general population. Patients with RA
may experience disability due to joint involve-
ment as well as multiple extra-articular comor-
bidities [1]. Although great advances have been
made over the last 20 years in the understanding
of the pathogenesis and in the management of
RA, life expectancy is still lower than that of the
general population [2]. Cardiovascular (CV)
comorbidities are a common extra-articular
manifestation of RA (Table 1) [3, 4]. Among
RA-related cardiac diseases, accelerated
atherosclerosis, particularly in the form of coro-
nary artery disease, has the greatest clinical
impact because it is the main cause of premature
mortality in most autoimmune rheumatic dis-
eases [5]. Comparedwith the general population,
patients with RA experience a doubled risk of
developing aCVdisease (CVD) [6], with 60%and
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48% increases, respectively, in risk of CVD mor-
tality andmorbidity [7, 8]. The excess CV burden
in patients with RA is not fully explained by tra-
ditional CV risk factors although their impact in
patients with RA is high [9]. Growing evidence
supports the view that RA behaves as an inde-
pendent risk factor for the development of CVD
similarly to diabetes mellitus [10].
There are many issues that need to be con-
sidered when CVD risk is evaluated in RA.
Clinical presentations are often atypical in RA
patients, thus contributing to substantially
underdiagnosed and untreated CVD [11, 12].
Subclinical CVD may be overlooked with tradi-
tional imaging techniques, whereas newer
diagnostic tools may show the presence of
subclinical myocardial dysfunction and
microvascular disease are often present in these
patients (Table 1) [13].
Aside from pharmacological and non-phar-
macological interventions on traditional CV
risk factors, the control of disease activity and
inflammation in RA seems to play a pivotal role
in reducing CV risk [14]. In line with this view, a
very recent paper from Myasoedova et al.
reported an improved overall CV mortality in
patients with RA in recent years [15]. The rea-
sons of such findings need to be further exam-
ined, but an improved control of disease
activity in the latest years could be hypothe-
sized. The optimal management of CV risk and
comorbidities in RA is still open to debate. In
view of this unmet need, the European League
Against Rheumatism (EULAR) task force was
prompted by new evidence to perform an
update of the 2009 recommendations of CV risk
management in inflammatory joint diseases,
particularly in RA [16].
Table 1 Cardiac comorbidities in rheumatoid arthritis [3, 4]
Comorbidity Frequency Clinical
signiﬁcance
Treatment
Atherosclerotic
cardiovascular
disease
68% increase in risk of MI, 41%
increase in risk of CVA
High CV treatment, control of disease activity
with DMARDs
Pericarditis 20–50% at TTE Low NSAIDs, GC, control of disease activity
with DMARDs
Heart failure 87% increase in risk, DD[60%
at TTE
High if
atherosclerotic
CVD, DD rare
Control of disease activity with DMARDs,
avoid anti-TNF-alpha in severe CHF
(class IV)
Valvular disease Mitral regurgitation 80% at
TTE, valve nodules 30% at
TEE
Low Conservative treatment, valvular
substitution
Myocarditis Rare, associated with active
disease
Low GC, control of disease activity with
DMARDs
Cardiac
amyloidosis
Frequent in the past, now rare Low Control of disease activity with DMARDs
Conduction
abnormalities
Uncommon, mostly AV block
or RBBB
Low Control of disease activity with DMARDs
AV atrioventricular, CHF congestive heart failure, CVA cerebrovascular accident, CVD cardiovascular disease, DD diastolic
dysfunction, DMARDs disease-modifying anti-rheumatic drugs, GC glucocorticoids, MI myocardial infarction, NSAIDs
non-steroidal anti-inﬂammatory drugs, RBBB right bundle branch block, TEE transesophageal echocardiography, TNF
tumor necrosis factor, TTE transthoracic echocardiography
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We aim to provide a practical update on the
main aspects of prevention and treatment of CV
comorbidities in RA, focusing on atherosclerotic
CVD, in order to help the clinician in the man-
agementof this condition inaday-to-day setting.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Pathogenesis
The pathogenic mechanisms underlying acceler-
ated CVD in RA are complex and not completely
clarified (Fig. 1). Several genetic polymorphisms
at loci either inside or outside the major histo-
compatibility complex (MHC) region have been
associated with both atherosclerosis and RA.
Association between the shared epitope alleles of
HLA-DRB1 * 04 and endothelial dysfunction and
CV risk has been reported. Polymorphisms out-
side the MHC region were associated with dys-
lipidemia and hypertension and even with the
riskofCVevents independentlyof thepresenceof
traditional risk factors in patients with RA [4].
The absolute CV risk for patients with RA is
increased when compared with the general
population even after adjusting for traditional CV
risk factors. Nevertheless, traditional risk factors
are important contributors to the CV risk of
patients with RA and further non-traditional risk
factors have been more recently identified
(Table 2) [5]. In anumberof autoimmune systemic
diseases, immune mechanisms and inflammation
maycontribute toacceleratedatherosclerosis since
the early phase of the disease [5, 17]. Extensive
cross-talk between the coagulation pathway and
inflammation is clear and it is particularly relevant
in the case of RA [18]. The activation of the
inflammatory cytokine network induces a
pro-thrombotic environment characterized by
insulin resistance, dyslipidemia, endothelial dys-
function, and alterations of coagulation and fibri-
nolytic systems [19]. Inflammation is the main
culprit in both RA and atherosclerosis [20].
Recently, also citrullination and carbamylation
have been suggested as commonpathways linking
RA and coronary heart disease [21].
Defining the Problem: Quantifying CVD
Risk in RA
It is now accepted that RA should be considered
as an independent risk factor for the
Fig. 1 The contribution of traditional and non-traditional
risk factors and anti-rheumatic therapies to cardiovascular
risk in patients with rheumatoid arthritis. CV
cardiovascular, COXIBs cyclooxygenase-2 inhibitors,
DMARDs disease-modifying anti-rheumatic drugs,
NSAIDs non-steroidal anti-inﬂammatory drugs
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Table 2 Traditional and non-traditional cardiovascular risk factors in rheumatoid arthritis [5, 15, 21, 22]
CV risk factors Evidence Intervention
Traditional
Cigarette smoking Strong association with CV outcome
predictors such as RF and ACPA, response
to anti-TNF-alpha and cachexia; trigger for
the increase of disease activity; interference
with antimalarial therapy
Smoking cessation
Arterial hypertension Association with NSAIDs and DMARDs;
activation of intracellular signaling pathways
of inﬂammation that lead to increased
vascular peripheral resistance; speciﬁcally
associated polymorphisms described
Anti-hypertensive treatment following
guidelines for the general population
Dyslipidemia Not only the quantity but also the quality,
structure, and function of lipids are affected
Diet, statins, start treatment following
guidelines for the general population
Type II diabetes
mellitus
Association with corticosteroid therapy GC for the shortest time and the lowest dose,
biological therapy and hydroxychloroquine
seem to have a protective effect
Body mass index Both BMI[25 or\20 kg/m2 are associated
with increased mortality
Diet, lifestyle changes
Physical inactivity Association with increased mortality Lifestyle changes
Hyperhomocysteinemia Prothrombotic effect only if
hyperhomocysteinemia
No evidence of prothrombotic effect with the
MTHFR mutation
Folic acid supplementation
Repeated checks in patients treated with
methotrexate
Non-traditional
Anti-phospholipid
antibodies
Prothrombotic effect; no association with
accelerated atherosclerosis
Hydroxychloroquine may prevent thrombosis
in aPL carriers; in APS follow international
guidelines
Depression Depression may associate with an
inﬂammatory condition; pain and fatigue are
ampliﬁed
Treatment of depression in order to resume
normal activities and physical exercise
Thyroid function Autoimmune hypothyroidism may be
associated with other autoimmune
conditions such as RA
Treatment of the underlying disease
Periodontitis P. gingivalis in atherosclerotic plaques;
periodontitis is associated with worse
outcome
Non-surgical treatment of periodontitis is
associated with better RA outcome
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development of CVD and the European Society
of Cardiology (ESC) guidelines have been
reviewed accordingly [22]. The Systematic Cor-
onary Risk Evaluation (SCORE) system is a CV
risk-assessment tool developed for the general
population that is based on the identification of
selected unmodifiable (gender, age) and modi-
fiable factors (smoking status, systolic blood
pressure, and lipid profile) [23]. The risk pre-
diction models available for the general popu-
lation have demonstrated to underestimate CV
risk in RA patients [24], therefore, many
attempts have been made to produce RA-speci-
fic risk calculators [25–27] and correction factors
have been suggested [23, 27, 28]. The addition
of a 1.5 multiplication factor to the SCORE
system in patients with RA has been approved
by the European League Against Rheumatism
(EULAR) for daily implementation in clinical
practice. The correction must be applied inde-
pendently of disease-related criteria, although
high disease activity and duration ([10 years),
the presence of rheumatoid factor (RF) and/or
anticitrullinated peptide antibodies (ACPA) and
extra-articular manifestations deserve attention
[16, 29]. However, a recent study by Crowson
et al. demonstrated that RA-specific risk calcu-
lators, including EULAR 1.5 multiplier, do not
predict CV risk more accurately than risk cal-
culators developed for the general population
[30].
According to EULAR recommendations [16],
the assessment of RA patients should be war-
ranted from once every 5 years if the risk is low
to moderate, since the impact of narrower
screening intervals is not evidence-based [31] or
more often for patients with intermediate and
high risk (Fig. 2). EULAR recommendations do
not specify the frequency, but we suggest at
least once per year. When CVD risk exceeds a
10-year risk of 5% for fatal CVD events with
SCORE, lifestyle changes and treatment with
lipid-lowering agents is recommended. How-
ever, a healthy lifestyle is emphasized for all
persons, including patients at low and inter-
mediate CV risk. Additionally, ESC guidelines
on CVD prevention in clinical practice also
recommends CVD risk stratification for patients
with hypertension.
Other non-RA conditions should be consid-
ered, such as diabetes mellitus and chronic renal
disease, as well as the presence of ongoing
cancer treatments, periodontitis, obstructive
sleep apnea syndrome, and erectile dysfunction.
Family history, ethnicity, and psychosocial fac-
tors (e.g., socio-economic status, mood disor-
ders), which may be of difficult quantification,
should be considered as well. Body weight is
generally measured by the body mass index
(BMI), which is optimal between the values of
20.0 and 25.0 kg/m2. However, the use of BMI
in RA patients may raise concerns, especially
when therapy with glucocorticoids is long-s-
tanding body fat storing may be modified (e.g.,
Cushing-like syndrome). The waist circumfer-
ence to quantify the body fat stored in the
abdomen (intra-abdominal fat) may be a valu-
able choice in such patients [32]. On the other
hand, RA cachexia due to long-lasting disease
activity may be a major issue [33] and should be
considered a CV risk factor as well.
The impact on CVD risk assessment of other
biomarkers, such as inflammatory (e.g.,
high-sensitivity C-reactive protein, fibrinogen),
Table 2 continued
CV risk factors Evidence Intervention
Obstructive apnea Association with inﬂammatory rheumatic
diseases; a risk factor for the development of
CV comorbidity
The use of TNF-alpha antagonists is associated
with the reduction of the prevalence of this
condition among patients
ACPA anti-citrullinated peptide antibodies, aPL anti-phospholipid antibodies, APS anti-phospholipid syndrome, BMI body
mass index, CV cardiovascular, DMARDs disease-modifying anti-rheumatic drugs, GC glucocorticoids, MTHFR
methylene-tetrahydrofolate reductase, NSAIDs non-steroidal anti-inﬂammatory drugs, RA rheumatoid arthritis, RF
rheumatoid factors, TNF tumor necrosis factor
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lipid-related (e.g., apolipoproteins) and throm-
botic biomarkers (e.g., homocysteine, lipopro-
tein-associated phospholipase A2) is still
uncertain [34–37]. Genetic analysis for
methylene-tetrahydrofolate reductase (MTHFR)
mutation is not routinely recommended unless
hyperhomocysteinemia is present because the
former alone is not associated with CV risk [38].
Many imaging tools such as coronary artery
calcification by multi-slice computed tomogra-
phy [39], intima–media thickness by carotid
ultrasound [40], arterial stiffness with aortic
pulse wave velocity or arterial augmentation
index, ankle–brachial index [41–43], and
echocardiography [44], have been proposed to
measure subclinical vascular damage in RA.
Among these, only carotid ultrasound has been
included in EULAR recommendations for clini-
cal practice, based on the evidence that carotid
plaques in RA are associated with disease dura-
tion, disease activity, and ischemic heart disease
with poor CVD-free survival [45–47]. Therefore,
the routinely use of biomarkers/imaging tools
regardless of first-screening CV risk assessment
is not recommended in daily practice [22].
When present, unfavorable markers may be
added to the general CVD risk assessment in
order to guide therapy in specific situations
(e.g., renal, cardiac biomarkers) or to adjust
CVD risk assessment calculated by SCORE
system.
When performing the SCORE risk assess-
ment, clinicians should be aware of possible
limitations in its use in RA patients. Cholesterol
and triglycerides levels should be measured
during the inactive phase of disease in order to
limit the potential effect of systemic inflam-
mation [48–50] or of concurrent therapy tar-
geting disease remission [51, 52] on lipid profile.
During active disease, the ratio of total choles-
terol:high-density lipoprotein-cholesterol could
be more reliable than the individual lipid
parameters [53]. A re-assessment of CVD risk
should be performed after achieving a
stable control of disease activity. Furthermore,
peculiar patterns of hypertension may be
observed in active RA and approaches different
from office blood pressure measurements (e.g.,
24-h ambulatory monitoring) may be consid-
ered [54]. However, SCORE has not been yet
validated in RA. Furthermore, as RA mainly
affects women, CV risk may be underestimated
Fig. 2 Practical approach for cardiovascular risk assessment and management in patients with rheumatoid arthritis. CV
cardiovascular, SCORE Systematic COronary Risk Evaluation [23]
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even after the EULAR correction is applied. For
example, young female patients may total a
SCORE of 0, with a null effect of the 1.5 EULAR
correction. In these cases, or when the SCORE is
around thresholds, the detection of plaques by
carotid ultrasound can be useful to raise the
prediction of CVD in RA patients.
Coping with the Problem: Practical
Management of CVD in RA
Prevention and Treatment of CVD in RA
Currently, there are no clinical trials specifically
designed to define the optimal management of
CVD co-morbidities in RA. Therefore, most
interventions are extrapolated from studies and
international guidelines on general population
and based on expert opinion.
Prevention of Cardiovascular (CV) Disease in
Rheumatoid Arthritis (RA): Lowering the
Risk CVD risk is expected to be lower when
disease activity is properly controlled, since an
association between inflammatory burden and
CVD risk has been extensively reported in RA
[55, 56]. The number and duration of disease
flares over time seem to contribute to the risk of
CVD, although disease duration does not seem
to have an independent effect [55, 57]. Thus,
chronic inflammation should be considered as a
modifiable risk factor, and reduction of inflam-
mation by disease-modifying antirheumatic
drugs (DMARDs) plays a pivotal role in CVD risk
management. In this view, an early diagnosis
and an aggressive treatment of RA may con-
tribute to control disease activity as well as to
contain the CVD risk.
As in the general population, patients cate-
gorized at high or very high CV risk (e.g.,
SCORE C5% and[10%, respectively) should be
promptly treated for existing CVD risk factors
[16]. Regardless of risk level, all patients should
receive lifestyle recommendations and be edu-
cated about the importance of regular exercise,
healthy diet, and smoking cessation. Further to
healthy lifestyle education, cognitive behav-
ioral methods may improve compliance [58].
Physical inactivity may be a major issue in
patients with RA, since it may contribute to
raise the CVD risk [59]. Moreover, regular exer-
cise has been shown to reduce inflammation in
patients with RA, probably in relation with
body fat [60]. Contraindications to high-inten-
sity exercise have not been reported [61]. The
ESC recommendations seem reasonable: at least
150 min a week of moderate-intensity or 75 min
a week of vigorous-intensity aerobic physical
activity [22]. Isotonic physical exercise may
help to stimulate bone formation and reduce
bone loss. To avoid the risk of falls in elderly
patients, neuromotor exercise such as tai chi,
yoga, and recreational activities, may be
appropriate and may help in improving balance
and motor skills.
Dietary habits, including specific dietary
patterns such as a Mediterranean diet, have
demonstrated to reduce CV risk [62] and also
demonstrated to help control disease activity in
RA [63]. Although there is no specific evidence
on the effect on CVD risk in RA patients, EULAR
recommends a Mediterranean diet to patients
with RA [16]. A limited intake of sodium (opti-
mal as low as 3 g/day) and an optimal intake of
vitamin D and omega-3 acids (primarily from
the diet) should be recommended as for the
general population. Elevated serum levels of
homocysteine have long been associated with
the risk of CVD and stroke [64]. Homocysteine
levels may be higher in patients treated with
methotrexate, which is a folic acid antagonist
that interferes with homocysteine metabolism
by reducing the activity of MTHFR [65].
Although a recent Cochrane Review found no
evidence to suggest that homocysteine-lower-
ing interventions given alone or in combina-
tion could be effective in preventing CV events
[66], in the course of treatment with
methotrexate, we always recommend the diet-
ary supplementation with folic acid.
Smoking cessation is mandatory in RA
patients, as it is known to have a role in disease
pathogenesis [67], and it is the most cost-effec-
tive strategy. Nicotine replacement therapy as
well as electronic cigarettes might be considered
for helping in smoking cessation [68]. Passive
secondary smoking carries significant risk [69],
and non-smoker RA patients need to receive
protection.
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There is no evidence that the management
of hypertension and hyperlipidemia, as well as
the treatment thresholds, should differ in RA
patients as compared to non-RA patients [16].
However, it is evident that hypertension is
underdiagnosed and undertreated in patients
with RA [70]. Previous recommendations about
the preferable use of angiotensin-converting
enzyme inhibitor and angiotensin II receptor
blockers have not been confirmed as the main
benefits of blood-pressure-lowering treatment
are expected to be due to lowering of blood
pressure per se, and the choice of the drug
should be guided by specific conditions (i.e.,
clinical CV events or asymptomatic organ
damage such as microalbuminuria, left ventric-
ular hypertrophy). Statins have been largely
studied in RA patients and their efficacy in
reducing cholesterol levels and CVD morbidity
and mortality was reported to be similar when
compared with non-RA controls with analogous
adverse reactions [71]. Particularly, myalgia and
rhabdomyolysis do not seem to be more fre-
quent in RA patients than in the general pop-
ulation [72]. Moreover, statins have shown
desirable anti-inflammatory properties, which
have been advocated to have an effect on RA
even greater when combined with DMARDs
[73]. However, this overall effect needs to be
confirmed and non-statin drugs may also be
considered as valuable choices [74]. Finally,
clinicians should always pay attention to the
impact of anti-rheumatic drugs such as gluco-
corticoids (GC), non-steroidal anti-inflamma-
tory drugs (NSAIDs), cyclosporine and
leflunomide on hypertensive state, and lipid
profile (e.g., tocilizumab, tofacitinib) when RA
patients are evaluated [16].
As in the general population, anti-platelet
therapy should not be routinely administered as
primary prevention due to the lack of evidence
and the increased risk of major bleeding, but
should instead be given after an episode of
myocardial infarction (MI), stroke, or peripheral
artery disease following the guidelines for the
general population [22].
Treatment of Cardiovascular (CV) Diseases in
Rheumatoid Arthritis (RA): Ischemic Heart
Disease and Heart Failure Patterns of clinical
care and disease-specific intervention may vary
in patients with RA when compared with the
general population. Although RA patients
receive similar care to non-RA patients, out-
comes are worse [12]. This may be due to
undertreatment or underestimation of CV risk
[70, 75]. Evidence from the general population
demonstrates that women are often under-
treated, probably due to the common belief that
they are more protected by CV risk, which is
delayed by 10 years [76]. This false belief may be
particularly dangerous in patients with RA,
which predominantly affects women in their
third–fifth decades and leads to accelerated CV
comorbidity and mortality. Furthermore, CVD
in women often presents as MI associated with
non-obstructive coronary arteries, spontaneous
coronary artery dissection, heart failure with
preserved ejection fraction, and peripheral
arterial disease [76–78]. This could be a possible
explanation of the less-effective treatment in RA
patients and should be considered when
choosing an intervention from the evidence
coming from the general population, where
men are more affected by CVD and specifically
by atherosclerotic coronary artery disease. Apart
from CV risk reduction and disease-specific
interventions chosen after a careful consulta-
tion with an expert cardiologist, tight control of
disease activity should be achieved with
RA-specific treatment. According to regulatory
agency safety warnings, in patients with severe
congestive heart failure (New York Heart Asso-
ciation class III/IV), the use of a combination of
conventional synthetic (cs)DMARDs with bio-
logical (b)DMARDs such as tumor necrosis fac-
tor-inhibitors (TNFi) or tofacitinib should be
preferred over TNFi in patients [79]. However,
due to the lack of univocal evidence, TNFi could
probably be used safely in compensated heart
failure or in the absence of other reasonable
options.
Treatment of Patients with Rheumatoid
Arthritis (RA): Considering Cardiovascular
(CV) Risk
Remission or low disease activity are desirable in
RA because control of systemic inflammation
likely contributes to lower CV risk and mortality
as well in patients with RA. The use of drugs
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that may increase CV risk should be limited.
However, the type of treatment may be less
important than reducing inflammation itself for
CVD risk management in RA [19, 80]. In line
with the most recent international recommen-
dations, GC and csDMARDs are considered the
first-line therapy to induce remission in RA and
bDMARDs are the current mainstay of treat-
ment of moderate-to-severe RA [81]. NSAIDs are
considered a valuable yet supportive short-term
treatment and their long-term use is usually
discouraged (Table 3).
Non-Steroidal Anti-Inflammatory Drugs
(NSAIDS) and Glucocorticoids (GC) The
long-term use of NSAIDs and GC has been
associated with increased CV risk [14, 82]. Both
non-selective and selective NSAIDs have adverse
effects on CVD outcomes in patients with RA.
Diclofenac is contraindicated in patients with
documented CVD (congestive heart failure,
ischemic heart disease, peripheral arterial dis-
ease, or cerebrovascular disease), and new evi-
dence supports similar restrictions for ibuprofen
use. Celecoxib (or low-dose GC) should be
considered in patients treated with warfarin,
other K-vitamin antagonists or clopidogrel.
Recently, in a randomized controlled trial, in
comparison with two widely used non-selective
NSAIDs—naproxen and ibuprofen—celecoxib
was non-inferior in CV safety and naproxen
treatment did not result in better CV differently
from previous studies [83]. Even acet-
aminophen, widely used as a safe analgesic may
interfere with antihypertensive treatments [84].
As far as GC treatment is concerned, the daily
and cumulative dose and the duration of treat-
ment specifically associated with a high CVD
Table 3 Effects of anti-inﬂammatory and disease-modifying anti-rheumatic drugs on cardiovascular risk in the management
of rheumatoid arthritis
Positive effects Negative effects
NSAIDs Acetylsalicylic acid is anti-platelet All other NSAIDs seem to increase CV risk by a
prothrombotic effect
COXIBs May ameliorate physical activity
resistance
Prothrombotic effect
Corticosteroids Reduced inﬂammation May increase risk of CV events, BMI, dyslipidemia, insulin
resistance, arterial hypertension
Methotrexate Disease activity reduction May increase homocysteinemia, which is prevented with folic
acid supplementations
Hydroxychloroquine Improved lipid proﬁle, reduced risk
of diabetes
May be responsible of cardiomyopathy although rarely
Cyclosporine Disease activity reduction Arterial hypertension
Leﬂunomide Disease activity reduction Arterial hypertension
Anti-TNF-alfa Disease activity reduction, reduced
insulin resistance
Contraindicated in severe CHF (class III/IV NYHA)
Abatacept Safe in CHF –
Tocilizumab Safe in CHF Cholesterol levels may increase but CV risk does not increase
Rituximab Safe in CHF –
BMI body mass index, CHF congestive heart failure, COXIB, selective cyclooxygenase-2 inhibitors, CV cardiovascular,
NSAIDs non-steroidal anti-inﬂammatory drugs, NYHA New York Heart Association
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risk have not been defined. However, it is
advisable that the daily dose and treatment
duration should be kept as low as possible [85].
Conventional Synthetic Disease-Modifying
Anti-Rheumatic Drugs (csDMARDs) The use
of csDMARDs is associated with a reduction of
CVD risk, particularly after long-term use [14].
Methotrexate is the csDMARDs of choice as part
of the first treatment strategy in RA [81] and its
use was shown to be associated with a reduction
of CVD risk [86]. Beneficial effects of
methotrexate on arterial stiffness as surrogate
marker of CVD risk have also been described
[87]. Among major csDMARDs, sulfasalazine
showed to contribute to reduce CVD risk with
lesser extent than methotrexate [88], yet data
are sparse consistently with its limited use in
RA. Interestingly, hydroxychloroquine showed
to improve lipid profile and to reduce the risk of
diabetes [89, 90]. Finally, cyclosporine and
leflunomide are well known to have a role in
development of hypertension and their use
should be avoided in RA patients, especially
when high blood pressure is documented
[91, 92].
Biological Disease-Modifying Anti-Rheumatic
Drugs (bDMARDs) The use of bDMARDs, such
as the TNFi, is associated with a significant
reduction in CVD risk in patients with RA, in
particular in those who respond to TNFi treat-
ment [93, 94]. These observations further sup-
port the view that the reduction in CV risk is due
to tight control of inflammation. Effects on sur-
rogate marker for CVD (e.g., carotid intima
media thickness, arterial stiffness)were described
in patients treatedwith TNFi andnon-TNFi, such
as tocilizumab and rituximab [95–101]. The lipid
increasing effect of bDMARDs is known and lipid
assessment during treatment, particularly with
tocilizumab, is mandatory [102]. However, the
impact of these changes onCVDoutcomes is still
to be defined, also in view of the overall safe
profile of these drugs [19, 80]. An overall increase
of lipid components was observed when using
TNFi and/or csDMARDs, but this may be coun-
terbalanced by an anti-atherogenic lipid profile
due to the improvement of the ratio between
total cholesterol (TC) and HDL [50]. Rituximab
and tocilizumab (and probably tofacitinib) are
associated with an overall increase of individual
lipid components without changes in TC/HDL
ratio, yet with no observed increase in CVD risk
[80]. In specific cases, statins are effective in
reducing lipid levels in patients receiving such
treatments [102].
CONCLUSIONS
Epidemiologic data demonstrate that CVD risk is
increased in RA patients compared to the general
population. Likely, this is due to common
underlying pathogenetic mechanisms. Control
of chronic inflammation is one of the targets to
ameliorate CV risk profile in RA patients. There-
fore, all RA patients should be assessed for CVD
risk to warrant an appropriate management and
to implement early strategies of prevention.
First-line screening assessment with SCORE
could be enough in daily clinical practice to
identify high-risk patients and to avoid delayed
treatment of RA patients, although it has not yet
been validated in RA and has some limitations.
Anti-inflammatory therapies and other non-tra-
ditional CV risk factors should be considered in
CVD risk assessment and outcomes of therapies.
Particularly, the choice of therapy should also be
based on the CV risk of each patient. Further
studies are needed to understand if CV comor-
bidities in RA patients should be treated differ-
ently from the general population.
Rheumatologists should ensure CV risk assess-
ment and an optimal targeted management of
RA, but also should cooperate with cardiologists,
general practitioners, and other specialists in a
multidisciplinary setting.
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